
MOG antibody-associated disease: immunotherapy reduces risk of recurrence
A New retrospective analysis of data from patients with myelin oligodendrocyte glycoprotein antibody disease (MOGAD) suggests that immunotherapy is associated with a lower risk of recurrence. However, the authors note that many MOGAD patients never experience a recurrence and that it is difficult to identify the patients who get a recurrence. MOGAD can cause optic […]